Brief: Rubius Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Of RTX-321
12/04/2021 14:04
April 12 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1
CLINICAL TRIAL OF RTX-321 FOR THE TREATMENT OF HPV 16-POSITIVE
CANCERS
Source text for Eikon: ID:nGNX5GtH0c
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft